New combo therapy shows promise for tough-to-treat liver cancer
NCT ID NCT04945720
First seen Feb 28, 2026 · Last updated Jun 10, 2026 · Updated 18 times
Summary
This study tested a combination of an immunotherapy drug (durvalumab) and chemotherapy delivered directly to the liver (HAIC) in 30 adults with advanced liver cancer that had spread into the main portal vein. The goal was to see if the combination could improve one-year survival. Participants received the treatment as an open-label, single-arm regimen. The study is completed, and results will help determine if this approach is safe and effective for this difficult-to-treat condition.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Department of Minimally Invasive and Interventional Radiology, Liver Cancer Study and Service Group, Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, 500060, China
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.